# Xometry, Inc.: financial statements, quarterly

XMTR · Nasdaq · CIK 1657573 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/xmtr.md) · [Financials](/companies/xmtr/financials.md) · [Filings](/companies/xmtr/filings.md) · [Insiders](/companies/xmtr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/xmtr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [119](/filings/0000950170-24-121514.md) | [128 d](/filings/0001193125-26-066959.md) | [123](/filings/0000950170-25-064464.md) | [133](/filings/0000950170-25-103000.md) | [142](/filings/0001193125-25-264651.md) | [149 d](/filings/0001193125-26-066959.md) | [151](/filings/0001193125-26-211872.md) | [163](/filings/0001193125-26-332776.md) | [181](/filings/0001193125-25-264651.md) | [192 d](/filings/0001193125-26-066959.md) | [205](/filings/0001193125-26-211872.md) | [229](/filings/0001193125-26-332776.md) |
| Cost of revenue | $m | [72.7](/filings/0000950170-24-121514.md) | [79.1 d](/filings/0001193125-26-066959.md) | [74.8](/filings/0000950170-25-064464.md) | [79.7](/filings/0000950170-25-103000.md) | [85.9](/filings/0001193125-25-264651.md) | [89.5 d](/filings/0001193125-26-066959.md) | [94.6](/filings/0001193125-26-211872.md) | [97.4](/filings/0001193125-26-332776.md) | [109](/filings/0001193125-25-264651.md) | [117 d](/filings/0001193125-26-066959.md) | [127](/filings/0001193125-26-211872.md) | [142](/filings/0001193125-26-332776.md) |
| Gross profit | $m | [46.2](/filings/0000950170-24-121514.md) | [49.1 d](/filings/0001193125-26-066959.md) | [47.9](/filings/0000950170-25-064464.md) | [52.9](/filings/0000950170-25-103000.md) | [55.8](/filings/0001193125-25-264651.md) | [59.0 d](/filings/0001193125-26-066959.md) | [56.3](/filings/0001193125-26-211872.md) | [65.2](/filings/0001193125-26-332776.md) | [72.0](/filings/0001193125-25-264651.md) | [75.2 d](/filings/0001193125-26-066959.md) | [78.5](/filings/0001193125-26-211872.md) | [87.2](/filings/0001193125-26-332776.md) |
| Research and development | $m | [8.5](/filings/0000950170-24-121514.md) | [8.9 d](/filings/0001193125-26-066959.md) | [9.6](/filings/0000950170-25-064464.md) | [10.0](/filings/0000950170-25-103000.md) | [9.3](/filings/0001193125-25-264651.md) | [10.4 d](/filings/0001193125-26-066959.md) | [11.2](/filings/0001193125-26-211872.md) | [11.0](/filings/0001193125-26-332776.md) | [12.5](/filings/0001193125-25-264651.md) | [12.1 d](/filings/0001193125-26-066959.md) | [11.4](/filings/0001193125-26-211872.md) | [13.0](/filings/0001193125-26-332776.md) |
| Operating income | $m | [(13.2)](/filings/0000950170-24-121514.md) | [(12.5) d](/filings/0001193125-26-066959.md) | [(17.9)](/filings/0000950170-25-064464.md) | [(15.3)](/filings/0000950170-25-103000.md) | [(11.5)](/filings/0001193125-25-264651.md) | [(11.5) d](/filings/0001193125-26-066959.md) | [(15.4)](/filings/0001193125-26-211872.md) | [(10.3)](/filings/0001193125-26-332776.md) | [(11.1)](/filings/0001193125-25-264651.md) | [(8.8) d](/filings/0001193125-26-066959.md) | [(5.2)](/filings/0001193125-26-211872.md) | [(5.5)](/filings/0001193125-26-332776.md) |
| Income tax | $m | [0.1](/filings/0000950170-24-121514.md) | [(0.6) d](/filings/0001193125-26-066959.md) | [0.0](/filings/0000950170-25-064464.md) | [(0.0)](/filings/0000950170-25-103000.md) | [0.0](/filings/0001193125-25-264651.md) | [(0.0) d](/filings/0001193125-26-066959.md) | [0.0](/filings/0001193125-26-211872.md) | [(0.0)](/filings/0001193125-26-332776.md) | [(0.0)](/filings/0001193125-25-264651.md) | [0.6 d](/filings/0001193125-26-066959.md) | [0.2](/filings/0001193125-26-211872.md) | [0.4](/filings/0001193125-26-332776.md) |
| Net income | $m | [(12.0)](/filings/0000950170-24-121514.md) | [(10.6) d](/filings/0000950170-24-023214.md) | [(16.6)](/filings/0000950170-24-057097.md) | [(13.7)](/filings/0000950170-24-094003.md) | [(10.2)](/filings/0000950170-24-121514.md) | [(9.9) d](/filings/0001193125-26-066959.md) | [(15.1)](/filings/0001193125-26-211872.md) | [(26.4)](/filings/0001193125-26-332776.md) | [(11.6)](/filings/0001193125-25-264651.md) | [(8.6) d](/filings/0001193125-26-066959.md) | [(5.3)](/filings/0001193125-26-211872.md) | [(5.3)](/filings/0001193125-26-332776.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [44.4](/filings/0000950170-23-062075.md) | [53.4](/filings/0000950170-25-026655.md) | [45.7](/filings/0000950170-24-057097.md) | [22.1](/filings/0000950170-24-094003.md) | [17.4](/filings/0000950170-24-121514.md) | [22.2](/filings/0001193125-26-066959.md) | [15.5](/filings/0000950170-25-064464.md) | [16.8](/filings/0000950170-25-103000.md) | [20.8](/filings/0001193125-25-264651.md) | [15.0](/filings/0001193125-26-332776.md) | [21.0](/filings/0001193125-26-211872.md) | [21.8](/filings/0001193125-26-332776.md) |
| Current assets | $m | [357](/filings/0000950170-23-062075.md) | [356](/filings/0000950170-25-026655.md) | [341](/filings/0000950170-24-057097.md) | [327](/filings/0000950170-24-094003.md) | [326](/filings/0000950170-24-121514.md) | [328](/filings/0001193125-26-066959.md) | [335](/filings/0000950170-25-064464.md) | [329](/filings/0000950170-25-103000.md) | [341](/filings/0001193125-25-264651.md) | [335](/filings/0001193125-26-332776.md) | [364](/filings/0001193125-26-211872.md) | [672](/filings/0001193125-26-332776.md) |
| Total assets | $m | [701](/filings/0000950170-23-062075.md) | [707](/filings/0000950170-25-026655.md) | [692](/filings/0000950170-24-057097.md) | [679](/filings/0000950170-24-094003.md) | [678](/filings/0000950170-24-121514.md) | [680](/filings/0001193125-26-066959.md) | [690](/filings/0000950170-25-064464.md) | [687](/filings/0000950170-25-103000.md) | [699](/filings/0001193125-25-264651.md) | [704](/filings/0001193125-26-332776.md) | [740](/filings/0001193125-26-211872.md) | [1,058](/filings/0001193125-26-332776.md) |
| Current liabilities | $m | [67.8](/filings/0000950170-23-062075.md) | [83.2](/filings/0000950170-25-026655.md) | [78.7](/filings/0000950170-24-057097.md) | [70.5](/filings/0000950170-24-094003.md) | [70.9](/filings/0000950170-24-121514.md) | [74.8](/filings/0001193125-26-066959.md) | [89.4](/filings/0000950170-25-064464.md) | [84.0](/filings/0000950170-25-103000.md) | [94.1](/filings/0001193125-25-264651.md) | [88.9](/filings/0001193125-26-332776.md) | [204](/filings/0001193125-26-211872.md) | [209](/filings/0001193125-26-332776.md) |
| Total liabilities | $m | [364](/filings/0000950170-23-062075.md) | [377](/filings/0000950170-25-026655.md) | [371](/filings/0000950170-24-057097.md) | [362](/filings/0000950170-24-094003.md) | [362](/filings/0000950170-24-121514.md) | [365](/filings/0001193125-26-066959.md) | [379](/filings/0000950170-25-064464.md) | [416](/filings/0000950170-25-103000.md) | [426](/filings/0001193125-25-264651.md) | [427](/filings/0001193125-26-332776.md) | [457](/filings/0001193125-26-211872.md) | [462](/filings/0001193125-26-332776.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [336](/filings/0000950170-23-062075.md) | [329](/filings/0000950170-25-026655.md) | [320](/filings/0000950170-24-057097.md) | [316](/filings/0000950170-24-094003.md) | [315](/filings/0000950170-24-121514.md) | [314](/filings/0001193125-26-066959.md) | [310](/filings/0000950170-25-064464.md) | [270](/filings/0000950170-25-103000.md) | [272](/filings/0001193125-25-264651.md) | [276](/filings/0001193125-26-332776.md) | [282](/filings/0001193125-26-211872.md) | [595](/filings/0001193125-26-332776.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.0) d](/filings/0000950170-24-121514.md) | [(1.3) d](/filings/0001193125-26-066959.md) | [(11.7)](/filings/0000950170-25-064464.md) | [(9.1) d](/filings/0000950170-25-103000.md) | [(3.6) d](/filings/0001193125-25-264651.md) | [9.1 d](/filings/0001193125-26-066959.md) | [(3.7)](/filings/0001193125-26-211872.md) | [(0.4) d](/filings/0001193125-26-332776.md) | [5.8 d](/filings/0001193125-25-264651.md) | [4.4 d](/filings/0001193125-26-066959.md) | [14.6](/filings/0001193125-26-211872.md) | [2.9 d](/filings/0001193125-26-332776.md) |
| Capital expenditure | $m | [3.6 d](/filings/0000950170-24-121514.md) | [6.4 d](/filings/0001193125-26-066959.md) | [4.3](/filings/0000950170-25-064464.md) | [4.4 d](/filings/0000950170-25-103000.md) | [4.8 d](/filings/0001193125-25-264651.md) | [4.5 d](/filings/0001193125-26-066959.md) | [5.5](/filings/0000950170-25-064464.md) | [7.0 d](/filings/0000950170-25-103000.md) | [7.4 d](/filings/0001193125-25-264651.md) | [10.3 d](/filings/0001193125-26-066959.md) | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-25-264651.md) | [0.0 d](/filings/0001193125-26-066959.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-264651.md) | [0.0 d](/filings/0001193125-26-066959.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.4](/filings/0000950170-22-016645.md) | [44.0](/filings/0000950170-22-024582.md) | [46.8](/filings/0000950170-23-020561.md) | [47.1](/filings/0000950170-22-016645.md) | [47.3](/filings/0000950170-22-024582.md) | [47.7](/filings/0000950170-23-020561.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,123,556 at 2024-04-30, from the cover of the [10-Q filed 2024-05-09](/filings/0000950170-24-057097.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.